Prostate Cancer Outcomes Comparable for Transgender Women, Cisgender Men
By Elana Gotkine HealthDay Reporter
FRIDAY, July 26, 2024 -- Most prostate cancer outcomes do not differ significantly between transgender women (TGW) and cisgender (CG) men, including prostate cancer-specific mortality, according to a study published online July 21 in Cancer.
Margaret Meagher, M.D., from the University of California San Diego School of Medicine in La Jolla, and colleagues compared oncological characteristics and survival outcomes between TGW and CG men with prostate cancer using data from the Veterans Affairs Informatics and Computing Infrastructure database (1999 to 2020) and the Surveillance, Epidemiology, and End Results-Medicare database (2010 to 2017). The groups were matched in a 5:1 ratio (CG:TGW) based on age, race, year of diagnosis, and Charlson Comorbidity Index score. Data were included for 1,194 patients: 199 TGW and 995 CG.
The researchers found that there were no significant associations between transgender identity and metastatic presentation, high-risk localized disease, or prostate cancer-specific mortality. There was a significant association seen between transgender identity and improved overall survival.
"In contrast to previous studies, we did not detect worsened prostate cancer outcomes within [the transgender] community," the authors write. "These conflicting data highlight the need for further investigation."
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2024
Read this next
Stereotactic Body Radiotherapy Feasible After Radical Prostatectomy
TUESDAY, May 20, 2025 -- Post-radical prostatectomy (post-RP) stereotactic body radiotherapy (SBRT) is well tolerated, with patient-reported outcomes (PROs) comparable to those...
MRI-Guided Biopsy Linked to Durability of Active Surveillance in Prostate Cancer
MONDAY, May 19, 2025 -- Use of magnetic resonance imaging (MRI)-guided biopsy (MRGB) could increase the durability of active surveillance (AS) in men with prostate cancer...
Testosterone Use Not Tied to Gynecological Cancers in Transmasculine Individuals
FRIDAY, May 16, 2025 -- Short-term testosterone use among transmasculine and gender diverse (TMGD) individuals is not associated with an increased risk for gynecological cancers...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.